Futura Medical cheers a “very productive six months, delivering on strategic objectives”

Futura Medical’s James Barder talks to Proactive’s Katie Pilbeam about its interim results for the six months ended 30 June 2022.

He says it’s been a constructive and productive six months.The operational highlights include getting MED3000 ready to be the first pan-European topical treatment for erectile dysfunction (“ED”) available without a doctor’s prescription.

And in the US, Futura received highly positive results from the confirmatory Phase 3 clinical study, (FM71) for MED3000 for the treatment of ED meeting all primary and secondary endpoints in August.

You might like

© 2022 Stockmark.it The Latest StockMarket News and Interviews